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Fab glycosylation of immunoglobulin G
does not associate with improvement of
rheumatoid arthritis during pregnancy
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Abstract
Background: Changes in immunoglobulin G (IgG) constant domain (Fc) glycosylation are associated with
changes in rheumatoid arthritis (RA) disease activity in response to pregnancy. Here, we sought to determine
whether the same holds true for variable domain (Fab) glycosylation.
Methods: IgGs were captured from RA and control sera obtained before (RA only), during and after pregnancy,
followed by Fc and Fab separation, glycan release, and mass spectrometric detection. In parallel, glycans from
intact IgG were analysed. The data was used to calculate glycosylation traits, and to estimate the level of Fab
glycosylation.
Results: The overall level of Fab glycosylation was increased in RA patients compared to controls, while no
differences in Fab glycosylation patterns were found. For the Fc and intact IgG (Total) previously observed
differences in galactosylation and bisection were confirmed. Furthermore, increased galactosylation of Fc and
Total were associated with lower disease activity and autoantibody positivity. In addition, the change in Fc
galactosylation associated with the change in disease activity during pregnancy and after delivery, while this
was not the case for Fab.
Conclusions: In contrast to changes in Fc glycosylation, changes in Fab glycosylation are not associated with
improvement of RA during pregnancy and arthritis flare after delivery.
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Background
Rheumatoid arthritis (RA) is an autoimmune disease,
for which it is well known that patients may improve
during pregnancy [1]. The immunoglobulin G (IgG)
fragment crystallisable (Fc) N-glycan compositions,
specifically the levels of galactosylation and sialylation
(Fig. 1), have been recognised to be different in RA
patients compared to healthy controls and to be asso-
ciated with RA disease activity and its improvement
during pregnancy [2–4].
In addition to the Fc moiety, that always bears
N-glycans, the hypervariable region of the antigen-
binding fragment (Fab) may harbour N-glycans [5]. These
glycans are generally present on approximately 15–25%
of the Fab portions, and have been found to alter the
binding properties of antibodies to their antigen, as well
as effector functions, and are known to change during
pregnancy [6–10]. Interestingly, for rheumatoid arthritis-
specific autoantibodies (anti-citrullinated protein anti-
bodies (ACPA)) the vast majority has been shown to
carry these Fab glycans [11].
In view of the known differences between the Fc
N-glycans of RA patients and healthy controls, and its
association with disease activity and improvement
during pregnancy, we aimed to determine whether
similar changes and associations can be found regarding
the Fab N-glycans. In addition, the level of Fab glycosylation
was investigated.
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Methods
Study population and data collection
For the current study we used sera from the Pregnancy-
induced Amelioration of Rheumatoid Arthritis (PARA)
study, a prospective cohort study on pregnancy and RA
[12]. At all time points, disease activity (DAS28; based
upon a count of 28 swollen and tender joints and C-
reactive protein (CRP)) and medication was recorded.
For the analysis we selected a subset of RA patients (n =
33) with the most pronounced (> = 0.6) or no change in
disease activity, both during and after pregnancy, in
search of maximum contrast. Only sera obtained before
pregnancy, during the third trimester of pregnancy, and
26 weeks postpartum were analysed. In addition sera
obtained from 32 healthy pregnant volunteers were
analysed (third trimester and 6 months after delivery
only). All patients fulfil the 1987 American College of
Rheumatology criteria for RA. The study was in com-
pliance with the Helsinki Declaration and was approved
by the Ethics Review Board at the Erasmus University
Medical Center, Rotterdam, The Netherlands.
IgG capturing and N-glycan release
IgGs were affinity-captured in duplicate from human
serum in a 96-well format, as described before, with
minor modifications [9]. One set was used for IdeS
digestion to separate the Fab and Fc portions, whereas
the other set was kept intact to analyse the total IgG
glycans. Dried samples were reconstituted in 5 μL
phosphate-buffered saline and 10 μL 2% (w/v) sodium
dodecyl sulfate solution, instead of 10 and 20, respect-
ively. Similarly, PNGase F was added in 10 μL.
Sialic acid derivatization and HILIC enrichment
To prevent the loss of sialic acids in the mass spectro-
metric detection of released glycans a derivatization
protocol was applied as described before, with minor
modifications [9, 13]. Briefly, 2 μL released glycans
were added to 20 μL ethyl esterification reagent in a
V-bottom 96-well plate, and incubated at 37 °C for 1 h.
After the incubation 20 μL acetonitrile was added. Ethyl
esterified N-glycans were purified from the reaction
mixture using hydrophilic interaction liquid chroma-
tography (HILIC) solid phase extraction (SPE) with a
piece of cotton thread as the solid phase in a micro tip
as described before [9].
MALDI-TOF-MS and data processing
Five microliter of eluate was mixed on the spot with
sodium hydroxide-spiked Super-DHB matrix (Sigma-
Aldrich, St. Louis, MO, USA) on an AnchorChip plate.
Automated matrix-assisted laser desorption/ionization
(MALDI)-time of flight (TOF) mass spectrometry
(MS) measurements were performed summing 10,000
shots per spot with 250 shot steps and a full spot
random walk. Details on data processing, extraction,
and the calculation of glycosylation traits are described
in Additional file 1.
Fig. 1 Schematic representation of immunoglobulin G. Indicated is what is generally considered as the Fc and Fab or F(ab’)2 portion. The glycans
of both Fc and Fab consist of the same building blocks, although the most abundant glycans may differ vastly in their appearance. This figure
was originally published in Bondt et al, Immunoglobulin G (IgG) Fab glycosylation analysis using a new mass spectrometric high-throughput
profiling method reveals pregnancy-associated changes. Mol Cell Proteomics. 2014; 13:3029–3039. © the American Society for Biochemistry and
Molecular Biology, and slightly adapted for the current manuscript
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Statistical analysis
Statistical analysis was performed in Stata 13SE (Stata-
Corp, College Station, TX, USA). Bonferroni correction
for multiple testing was performed throughout, with final
significance thresholds depicted in the tables with results.
First, a Wilcoxon rank-sum test was performed to explore
the differences in glycosylation between RA patients and
healthy controls outside pregnancy, at ≥26 weeks after
delivery. Next we investigated which clinical covariates
(use of medication, autoantibody (AAb) positivity, age at
delivery and disease activity) were associated with the gly-
cosylation in RA patients using linear regression analysis.
To study changes in glycosylation over time the Wilcoxon
matched-pairs signed-rank test was used, comparing pre-
conception with the third trimester for the patients, and
third trimester with 26 weeks postpartum for both pa-
tients and controls. Association of the changes in glycosyl-
ation over time and the accompanying changes in disease
activity were explored using Spearman correlation.
Results
Response during pregnancy and flare after delivery
Clinical characteristics of the patients and controls are
given in Additional file 1: Table S1. The patients who
improved (n = 14) during pregnancy showed a mean
decrease in DAS28 (delta DAS28; ΔDAS) of -1.7 (SD
0.5), whereas the nine patients that worsened showed a
ΔDAS of +1.6 (SD 0.5). Ten patients did not change
during pregnancy (ΔDAS = 0.0; SD 0.4). After delivery
the 12 patients that flared had a mean ΔDAS of +1.5
(SD 0.8), while the 12 improving patients showed a ΔDAS
of −1.5 (SD 0.6). Nine patients without a change in disease
activity between the third trimester and 6 months postpar-
tum (ΔDAS = −0.1; SD 0.4) were selected.
Fab glycosylation is higher in RA patients outside
pregnancy when compared to controls, yet with
similar glycans
The calculated level of Fab glycosylation in the patients
(21.4%; [IQR 19.5–25.4%]) was significantly higher than
in controls (16.5%; [IQR 13.3–18.2%]) at the non-
pregnant time point 26 weeks postpartum (Tables 1, 2
and 3). However, no differences between the levels of
galactosylation, sialylation, fucosylation or presence of
bisecting N-acetylglucosamine were observed for the
Fab glycosylation (Tables 1, 2 and 3) compared between
healthy controls and RA patients. However, for both Fc
and total IgG (Total) there was a lower level of galacto-
sylation and higher level of bisection in RA patients
compared to the healthy controls.
Galactosylation of Fc and intact IgG, but not Fab, associate
with disease activity and autoantibody positivity
In addition, it was explored which clinical covariates were
associated with the levels of the calculated glycosylation
traits at 26 weeks postpartum. Covariates were first tested
univariate, and those with p <0.2 were included in the
multivariate analysis. No Fab glycosylation models
Table 1 Median percentages and corresponding interquartile ranges for all time points and glycosylation traits
Healthy RA
3rd trima 26 wkpp pre-conception 3rd trim 26 wkpp
Median (%) IQR Median (%) IQR Median (%) IQR Median (%) IQR Median (%) IQR
Fc
Galactosylation 81.5 [78.1–83.2] 71.6 [67.9–74.7] 60.8 [52.2–64.3] 73.6 [66.5–79.5] 61.0 [56.8–66.7]
Sialylation 18.4 [17.1–20.5] 13.1 [11.5–15.8] 11.0 [9.0–13.1] 16.0 [14.0–19.7] 11.5 [9.4–14.1]
Fucosylation 96.8 [95.8–97.4] 97.3 [96.6–98.0] 97.9 [97.5–98.3] 97.5 [96.5–98.0] 97.7 [97.2–98.2]
Bisection 8.7 [7.3–9.7] 9.2 [8.3–10.5] 10.3 [9.0–11.5] 8.6 [7.4–10.2] 11.0 [9.5–13.4]
Total
Galactosylation 82.9 [80.6–84.6] 74.8 [70.3–77.0] 66.0 [59.9–69.0] 77.5 [73.5–82.2] 68.6 [59.1–73.5]
Sialylation 26.2 [23.9–28.7] 21.3 [19.4–22.6] 20.8 [19.1–23.8] 27.3 [24.4–28.4] 22.6 [20.0–24.5]
Fucosylation 95.4 [94.7–96.2] 96.5 [95.5–97.2] 96.9 [96.2–97.3] 96.2 [95.4–96.7] 96.7 [96.0–97.1]
Bisection 12.6 [10.6–14.1] 14.8 [13.3–17.3] 18.1 [15.8–19.8] 15.2 [13.6–17.7] 18.1 [16.8–19.6]
Fab
Galactosylation 96.8 [96.3–97.0] 97.2 [96.5–97.8] 96.6 [95.7–97.7] 97.3 [96.9–97.8] 96.8 [96.0–97.3]
Sialylation 81.6 [80.4–84.3] 79.0 [77.8–82.6] 79.7 [77.0–81.1] 82.7 [80.6–84.6] 80.2 [76.9–81.6]
Fucosylation 70.6 [68.0–75.3] 76.6 [74.5–80.6] 75.6 [71.9–80.5] 73.2 [61.6–75.8] 77.7 [72.8–79.7]
Bisection 37.0 [36.1–41.4] 46.6 [41.7–52.2] 51.5 [46.5–55.2] 42.1 [33.8–44.4] 52.2 [46.7–54.6]
% glycosylation 17.6 [13.7–21.0] 16.5 [13.3–18.2] 22.0 [18.7–27.4] 28.0 [23.3–32.7] 21.4 [19.5–25.4]
aAbbreviations: trim trimester, wkpp weeks postpartum, IQR interquartile range
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remained significant after Bonferroni correction. However,
for galactosylation of both Fc and Total multivariate
models could be composed with R2 values of 0.4 and 0.5,
respectively. For these models the main contributing fac-
tors were disease activity (beta = −0.5) and autoantibody
positivity (beta = +0.4). The results for all multivariate
models are shown in Additional file 1: Table S2.
Fab glycosylation changes during pregnancy and after
delivery are not associated with changes in disease activity
Galactosylation and sialylation of Fab, Fc and Total in-
creased between pre-conception and the third trimester
of pregnancy in RA patients (Tables 1, 2 and 3; Fig. 2).
The opposite was observed after delivery in both pa-
tients and healthy controls, except for the Fab portion
where only a decrease in sialylation was observed. For
fucosylation and bisection a decrease during pregnancy
(RA only) and increase after delivery was observed for
Fab, Fc and Total, in both patients and controls
(Tables 1, 2 and 3). In addition, during pregnancy an
increase in the level of Fab glycosylation was found in
RA patients. Of note, changes in glycosylation traits
that were high, e.g. Fab galactosylation and Fc fucosyla-
tion, were often not significant after Bonferroni correc-
tion (Tables 1, 2 and 3; Fig. 2).
The Fc galactosylation change from pre-conception to
the third trimester of pregnancy was negatively associ-
ated with the change in disease activity in that time span
(rho = −0.39, p = 0.029; Additional file 1: Table S3,
Table 2 Number of observations obtained for each category
and time point
Healthy RA
3rd trima 26 wkpp pre-conc. 3rd trim 26 wkpp
Fc
Galactosylation 29 25 33 31 33
Sialylation 29 25 33 31 33
Fucosylation 29 25 33 31 33
Bisection 29 25 33 31 33
Total
Galactosylation 25 25 33 30 31
Sialylation 25 25 33 30 31
Fucosylation 25 25 33 30 31
Bisection 25 25 33 30 31
Fab
Galactosylation 17 15 29 25 23
Sialylation 17 15 29 25 23
Fucosylation 17 15 29 25 23
Bisection 17 15 29 25 23
% glycosylation 15 15 29 24 21
aAbbreviations: trim trimester, wkpp weeks postpartum, pre-conc. pre-conception
Table 3 p values obtained for comparing glycosylation traits of controls vs. cases and over time
RA vs. healthy
at 26 wkppa
Healthy RA
3rd trim vs. 26 wkpp pre-conc. vs. 3rd trim 3rd trim vs. 26 wkpp
Fc
Galactosylation 0.000 0.000 0.000 0.000
Sialylation 0.077 0.000 0.000 0.000
Fucosylation 0.072 0.000 0.003 0.048
Bisection 0.004 0.003 0.000 0.000
Total
Galactosylation 0.001 0.000 0.000 0.000
Sialylation 0.179 0.000 0.000 0.000
Fucosylation 0.889 0.000 0.000 0.012
Bisection 0.000 0.000 0.000 0.000
Fab
Galactosylation 0.347 0.333 0.004 0.148
Sialylation 0.754 0.028 0.000 0.007
Fucosylation 0.709 0.005 0.000 0.003
Bisection 0.104 0.005 0.000 0.001
% glycosylation 0.002 0.401 0.009 0.249
For the comparison of RA vs. healthy a significance threshold of p <0.0038 was used (Bonferroni corrected for 13 tests), and for the time comparisons p <0.0013
(corrected for 42 tests). Significant observations are highlighted in bold font
aAbbreviations: wkpp weeks postpartum, trim trimester
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Additional file 1: Figure S1). The opposite was observed
for the change Fc and Total galactosylation from third
trimester to 26 weeks postpartum (rho = 0.48 and 0.62,
p = 0.006 and 0.001, respectively). For neither the Fab
glycosylation traits nor the Fab glycosylation level these
associations were observed.
Discussion
There is a strong association of IgG Fc galactosylation
with RA disease activity and the pregnancy-associated
improvement thereof [2, 3]. For the Fab portion of IgG
this has not yet been investigated. Therefore, we applied
our recently developed method for the analysis of Fab
glycosylation on samples from a set of RA and healthy
individuals in the context of pregnancy. Interestingly, we
found no qualitative differences in Fab glycosylation
between cases and controls nor an association with
changes in disease activity when we compared several
glycosylation traits. This may in part be caused by the
fact that Fab galactosylation and sialylation levels are
already high in the non-pregnant state, leaving less room
for a potential pregnancy-associated increase.
Since the Fab portion of IgG – in contrast to the Fc
portion – is not always glycosylated, the association
of changes in Fab glycosylation with disease activity
could be quantitative rather than qualitative. In line
with this, it has recently been published that the RA-
specific ACPA autoantibodies express high levels of
Fab glycosylation [11]. Indeed, in this study we did
observe increased levels of Fab glycosylation. How-
ever, even though the levels are higher in RA patients
compared to controls, they were not associated with
disease activity.
In the current study we chose to include only a limited
number of patients and time points. Therefore minor
associations between changes in RA disease activity and
changes in Fab glycosylation could have been missed.
Conclusions
In conclusion, this study clearly demonstrates that, in
contrast to changes in the glycosylation of the IgG Fc
domain, changes in the glycosylation of the IgG Fab
domain do not seem to play a major role in the
pregnancy-associated improvement of RA.
Fig. 2 Fc and Fab galactosylation and sialylation in RA and healthy controls. The percentages of galactosylation (yellow circle) and sialylation
(purple diamond) on the Fc show a clear increase during pregnancy (from pre-conception to the 3rd trimester; RA only) and decrease after
delivery (from 3rd trim to 26 weeks postpartum), as well as differences between cases and controls. No differences between cases and controls,
and only minor pregnancy-associated changes were observed for the Fab glycosylation. Abbreviations: pre-conc pre-conception, trim trimester,
wkpp weeks postpartum
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Additional files
Additional file 1: Additional Methods, Figure and Tables. The additional
file contains an addition to the Methods, a figure, and three additional
tables. (DOCX 262 kb)
Additional file 2: Data used for analysis. Contains the relative abundances
of the observed glycans and the calculated glycosylation traits for the RA
patients and healthy controls used in the current study. (XLSX 120 kb)
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